Sentia Medical Sciences is focused on developing innovative peptide therapeutics, specifically astressins, to manage and potentially cure stress-related diseases. These astressins are designed to block the action of corticotropin-releasing factor (CRF) and urocortins, which are key mediators in the body's stress response. By targeting both CRF1 and CRF2 receptors, Sentia aims to restore biological balance effectively and sustainably. The company addresses various conditions linked to stress, including Irritable Bowel Syndrome (IBS), postoperative complications, and congenital adrenal hyperplasia, among others.

The unique properties of astressins provide several advantages, particularly in terms of safety and long-lasting effects. Preclinical studies have shown no adverse effects from astressin B in various animal models, indicating a favorable safety profile. Additionally, astressins demonstrate prolonged action, which is crucial for maintaining homeostasis in patients. Unlike traditional non-peptide CRF antagonists, astressins interact directly with the hormone binding sites on the extracellular domain of the receptors, potentially enhancing receptor selectivity. This innovative approach positions Sentia at the forefront of developing effective treatments for stress-related conditions.

United States

Sentia Medical Sciences, Inc. is poised to be the world leader in the development of novel peptide therapeutics to manage and cure stress-related diseases by developing drugs called CRF peptides. The company is based out of La Jolla, California, United States.

Sentia Medical Sciences

Company Details